A new study has examined that brain activity in humans predict chances of relapsing after people quit smoking.
The study conducted at Penn State University suggested that quitting smoking sets off a series of changes in the brain and it may better identify smokers who will start smoking again i.e. a prediction that goes above and beyond today's clinical or behavioral tools for assessing relapse risk.
James Loughead, PhD, associate professor of Psychiatry, and Caryn Lerman, PhD, a professor of Psychiatry and director of Penn's Center for Interdisciplinary Research on Nicotine Addiction, found that smokers who relapsed within seven days from their target quit date had specific disruptions in the brain's working memory system during abstinence that separated them from the group who successfully quit. Such neural activity was mainly a decrease in the part of the brain that supported self-control and a boost in the area that promotes an "introspective" state could help distinguish successful quitters from those who fail at an earlier stage and serve as a potentially therapeutic target for novel treatments.
Researchers used functional magnetic resonance imaging (fMRI) to explore the effects of brief abstinence from smoking on working memory and its associated neural activation in 80 smokers seeking treatment. Participants were between 18 and 65 and reported smoking more than 10 cigarettes a day for more than six months.
Researchers determined predictive values of these two relapse models, as well as a new model that includes the working memory data. Using resampling methods that generate 1,000 replicates of the data from the 80 smokers, they found that incorporating the working memory-related brain activity resulted in an 81 percent correct prediction rate, a significant improvement over current models and without that data, the prediction values were 73 percent for the model of withdrawal symptoms and demographic/smoking history predictors, and 67 percent for demographic/smoking history predictors only.
The study is published in the journal Neuropsychopharmacology.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
